# Novel Biomarkers of Chronic Kidney Disease in Children

> **NIH NIH K08** · YALE UNIVERSITY · 2020 · $169,883

## Abstract

Project Summary. Candidate. I am a pediatric nephrologist at Yale University dedicated to improving outcomes
for children with chronic kidney disease (CKD). The goal of my application is to obtain mentored research training
to develop a biomarker-augmented risk prediction model of pediatric CKD progression for use in future clinical
trials. This research will build upon my prior training, which focused on the risk of CKD after acute kidney injury
and the use of biomarkers to predict renal outcomes in children. This proposal will provide me with hands-on
learning and formal didactic coursework in advanced statistics, biomarker methodology, and pediatric CKD. I will
also intensely focus on developing the professional skills necessary for establishing effective collaborations,
scientific writing, and obtaining funding to support my research. To accomplish my stated plan, I have the support
of my highly qualified primary co-mentors (Drs. Chirag Parikh and Susan Furth) and mentoring committee (Drs.
Haiqun Lin, Eugene Shapiro, and Prasad Devarajan) with interdisciplinary expertise in the fields of kidney injury
biomarkers, translational research, biostatistics, and pediatric CKD. This multidisciplinary mentorship along with
the highly skilled training environment at Dr. Parikh's, Program of Applied Translational Research will allow me to
conduct my proposed research and establish an independently funded research program.
Project. Progression of CKD in children leads to end stage renal disease (ESRD), which is associated with
mortality rates 30-150 times higher than the general pediatric population. The traditional biomarkers, serum
creatinine and proteinuria, are used to predict progression of CKD in clinical trials even though both correlate
poorly with the progression of CKD and the response to interventions. There are numerous candidate therapies
for CKD, but with a continued reliance on serum creatinine and proteinuria, clinical trials will likely continue to fail.
 The field of CKD biomarkers in children is a very promising area of research with a small amount of
resources invested to date. Predicting progression of CKD will allow clinicians to better time follow-up, referral for
transplant, and provide better guidance to families. More importantly, an optimal panel of biomarkers and risk
prediction model can replace proteinuria and serum creatinine in biomarker guided clinical trials. We plan to
measure urine and serum biomarkers of kidney injury, inflammation, repair, and fibrosis from the baseline
samples of the 869 children with CKD enrolled in the CKD in Children (CKiD) cohort and determine their
relationship with longitudinal measured GFR decline and incident ESRD. The optimal combination of biomarkers
plus clinical variables from 2/3rd's of the CKiD patients will yield a risk prediction model to predict CKD progression.
Our risk prediction model will be validated for longitudinal GFR decline, internally in 1/3rd of the CKiD patients, and
ex...

## Key facts

- **NIH application ID:** 9942416
- **Project number:** 5K08DK110536-05
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Jason Henry Greenberg
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $169,883
- **Award type:** 5
- **Project period:** 2016-08-18 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9942416

## Citation

> US National Institutes of Health, RePORTER application 9942416, Novel Biomarkers of Chronic Kidney Disease in Children (5K08DK110536-05). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9942416. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*